- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Novo Nordisk A/S (NYSE: NVO) hit a new 52-week high Tuesday as it is currently trading at $161.96, above its previous 52-week high of $161.05 with 18,599 shares traded as of 9:35 a.m. ET. Average volume has been 316,800 shares over the past 30 days. Novo Nordisk A/S has a market cap of $91.53 billion and is part of the health care sector and drugs industry. Shares are up 36.9% year to date as of the close of trading on Monday. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 27.2 and below the S&P 500 P/E ratio of 17.7.